2020
DOI: 10.1002/hep.31446
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study

Abstract: In December 2019, an outbreak of coronavirus disease 2019 (COVID‐19) emerged in Wuhan, China. Although it has been reported that some COVID‐19 patients showed elevated liver biochemistries, there are few studies regarding clinical features and prognosis of these patients. In this multicenter, retrospective study, we collected data on laboratory‐confirmed COVID‐19 patients from three hospitals in Wuhan, China, who died or were discharged between February 1, 2020, and February 20, 2020. The data on demographics,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
81
2
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 86 publications
(90 citation statements)
references
References 32 publications
4
81
2
1
Order By: Relevance
“…In our study, we found that abnormal liver biochemistry values on admission were significantly associated with outcomes during hospitalization such as prolonged length of stay, development of severe COVID-19, and more importantly, death. A previous study from China reported similar findings describing an association between mortality and abnormal liver tests on admission [ 22 ]. However, in that study, data were retrospectively collected; patients in the abnormal liver tests group presented a significantly higher proportion of chronic liver disease.…”
Section: Discussionsupporting
confidence: 67%
“…In our study, we found that abnormal liver biochemistry values on admission were significantly associated with outcomes during hospitalization such as prolonged length of stay, development of severe COVID-19, and more importantly, death. A previous study from China reported similar findings describing an association between mortality and abnormal liver tests on admission [ 22 ]. However, in that study, data were retrospectively collected; patients in the abnormal liver tests group presented a significantly higher proportion of chronic liver disease.…”
Section: Discussionsupporting
confidence: 67%
“…Among hospitalized patients with symptomatic COVID-19 disease, abnormal liver function tests (LFTs) are common ranging from 14%-53%. The most common observed abnormalities being hypoalbuminemia, elevated γGT, mild elevation of transaminases, and hyperbilirubinemia (22)(23)(24)(25)(26). Multiple studies have reported a correlation between COVID-19 severity and LFT abnormalities, with elevated aminotransaminase levels being more frequent in ICU inpatients, and patients requiring ventilation (27)(28)(29).…”
Section: Prevalence and Manifestations Of Liver Injury In Covid-19mentioning
confidence: 99%
“…Although these tests are the gold standard for COVID-19 diagnosis, they suffer from various practical issues, including reliability, resource adequacy, reporting lag, and testing capacity across time and space [ 5 ]. To help frontline clinicians diagnose COVID-19 more effectively and efficiently, other diagnostic methods have also been explored and used, including medical imaging (eg, X-ray scans and computed tomography [CT] scans [ 6 ]), lab testing (eg, various blood biochemistry analyses [ 7 - 10 ]), and identifying common clinical symptoms [ 11 ]. However, these methods do not directly detect the disease-causing SARS-CoV-2 virus or the SARS-CoV-2 antigen.…”
Section: Introductionmentioning
confidence: 99%